Good results shame there are no CR’s. I’d like to see them skip to Efti ketruda and chemo in a reg trial. That’s where the most good will be done.
But the pace this thing moves that won’t happen until the patents have run out.
The patent runways aren’t long enough anymore in oncology.
Also, with general health and improvement in existing SoC it’s difficult to know if a OS improvement is a result of the drug. Efti would do a lot better if it achieved CR’s but they are few and far between.
Good results shame there are no CR’s. I’d like to see them skip...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.010(2.78%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 36.0¢ | $563.7K | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 386559 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 261422 | 13 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |